Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.45 |
| ▸ | CASP6 | P55212 | 2/20 | 0.45 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FER | P16591 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 2/20 | 0.39 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555451 | 1.00 | GSK3B (0.52) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL7980321 | 0.79 | MAPT (0.56) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL3541281 | 0.79 | GSK3B (0.48) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL7008952 | 0.79 | LRRK2 (0.45) | GSK3BCASP3CASP7CASP6CASP8 | |
| SCHEMBL20505096 | 0.73 | MAPT (0.44) | GSK3BCASP3CASP7PDGFRAFER | |
| SCHEMBL20723 | 0.73 | MAPT (0.44) | GSK3BCASP3CASP7PDGFRAFER | |
| SCHEMBL8919879 | 0.71 | CYP1A2 (0.57) | GSK3BPDGFRAFERLTKCDK8 | |
| Phthalimide SCHEMBL64 | 0.70 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL11040503 | 0.70 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 | |
| Phthalimide SCHEMBL29366030 | 0.70 | GSK3B (1.00) | GSK3BCASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326721-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | Protego Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA, INC. | 2024-02-15 | — | — | US | claimed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | claimed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4326721-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | Protego Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA, INC. | 2024-02-15 | — | — | US | disclosed |
| CN-117482261-A | Combination therapy of radioimmunoconjugates and checkpoint inhibitors | 融合制药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117120086-A | Compositions and methods for cancer diagnosis | AOA DX公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117024469-A | Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments | 卫材R&D管理有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-111263747-B | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2023-10-27 | — | — | CN | disclosed |
| CN-112250692-B | Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments | 卫材R&D管理有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-07-08 | — | — | US | disclosed |
| CN-112390871-A | In vivo production of proteins | 现代泰克斯公司 | 2021-02-23 | — | — | CN | disclosed |
| CN-112386604-A | Modulators of cGAS | 纪念斯隆-凯特琳癌症中心 | 2021-02-23 | — | — | CN | disclosed |
| CN-111868044-A | Prins reaction and compounds useful for the synthesis of halichondrin macrolides and analogs thereof | 卫材R&D管理有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-111263747-A | Bifunctional chelate pharmacokinetics enhancement and uses thereof | 融合制药公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-110891614-A | IGF-1R monoclonal antibody and application thereof | 融合制药公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-110831632-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110785428-A | Methods and reagents for analyzing protein-protein interfaces | 锐新医药公司 | 2020-02-11 | — | — | CN | disclosed |
| WO-2019165158-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | IL6, IL6ST, IL2 | GSK3B 1419/4885CASP3 978/4885CASP7 617/4885 |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | IGLV6-57, TTR, MAP1LC3C | GSK3B 3649/4885CASP3 4035/4885CASP7 3095/4885 |
| US-20210206718-A1 | IL-6 INHIBITORS AND METHODS OF TREATMENT | IL6, IL6ST, IL2 | GSK3B 1419/4885CASP3 978/4885CASP7 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.